The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy

Melanoma and Skin CancerImmunotherapy

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Nat Med.

Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B

doi: 10.1038/nm.4466.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Immunotherapy

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Front Oncol.

Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA

doi: 10.3389/fonc.2018.00237.

Immunotherapy

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Expert Opin Biol Ther.

Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

Immunotherapy

The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy

Front Immunol.

Mengos AE, Gastineau DA, Gustafson MP

doi: 10.3389/fimmu.

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Related content

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Identification of essential genes for cancer immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Novel immunotherapy strategies for hepatobiliary cancers

The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer